Upper Tract Tumors
MR Imaging of the Upper Urinary Tract: Techniques, Diagnostic Performance, and Imaging Biomarkers.
- Details
MRI has become an increasingly important modality for evaluating the upper urinary tract. Although CT urography remains the standard imaging modality for assessing hematuria, MRI offers distinct advantages, including superior soft-tissue contrast, functional imaging capability, and a radiation-free evaluation, making it particularly valuable in certain clinical scenarios.
Longitudinal utDNA dynamics predict recurrence risk in upper tract urothelial carcinoma: A prospective cohort study.
- Details
Current surveillance of bladder recurrence for upper tract urothelial carcinoma (UTUC) is limited by invasiveness and sensitivity. There is an urgent need for noninvasive detection tool. We previously developed utLIFE, a urine tumor DNA model combining mutation profiling and fragmentomics.
Prognostic Impact of Tumor Size in Low-Risk Upper Tract Urothelial Carcinoma: A Multi-Institutional Analysis.
- Details
To evaluate the prognostic value of tumor size in patients with low-risk upper tract urothelial carcinoma (UTUC) undergoing radical nephroureterectomy (RNU).
A retrospective multicenter European analysis was conducted on 3,987 patients treated for UTUC at 17 academic institutions.
National Patterns and Predictors of Perioperative Intravesical Chemotherapy Use Following Nephroureterectomy for Upper Tract Urothelial Carcinoma.
- Details
Intravesical chemotherapy (IC) administered perioperatively after nephroureterectomy (NUx) for upper tract urothelial carcinoma (UTUC) reduces intravesical recurrence based on two randomized trials and is endorsed by contemporary practice guidelines.
Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study.
- Details
To evaluate real-world effectiveness and safety of adjuvant disitamab vedotin plus PD-1 blockade (ADC+ICI) versus gemcitabine/cisplatin (GC) in high-risk upper tract urothelial carcinoma after radical nephroureterectomy.
Robot-Assisted Versus Open Bladder Cuff Excision After Radical Nephroureterectomy: A Multicenter Study by the French Urothelial Cancer Committee - Beyond the Abstract
- Details
When disease travels downstream: The effect of intravesical recurrences in patients treated for upper tract urothelial carcinoma.
- Details
Treatment of upper tract urothelial carcinoma (UTUC) depends on risk stratification and tumour characteristics. Kidney-sparing surgery (KSS) is preferred for low-risk disease, whereas radical nephroureterectomy (RNU) is the standard for high-risk UTUC.
Healthcare Resource Utilisation in Patients with Upper Tract Urothelial Carcinoma.
- Details
Background: Upper tract urothelial carcinoma (UTUC) is rare, and contemporary data on real-world healthcare resource utilisation and costs are limited. The objective of this study is to describe long-term healthcare resource utilisation among patients with upper tract urothelial carcinoma (UTUC) and to identify clinical and treatment-related drivers of costs.
Nephroureterectomy with ileal cuff for upper tract recurrence after radical cystectomy: oncologic and survival outcomes.
- Details
Upper tract urothelial carcinoma developing after radical cystectomy presents a technical challenge because complete ureteral removal to the ileal anastomosis is often hindered by postoperative adhesions.
Metachronous contralateral recurrence in upper tract urothelial carcinoma: a multi-institutional competing-risks analysis from the ROBUUST 3.0 registry.
- Details
To define the incidence and predictors of metachronous contralateral recurrence in upper tract urothelial carcinoma and develop a risk score for tailored surveillance.
We analyzed 3024 patients surgically treated with curative intent from a multi-institutional registry (ROBUUST 3.